- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01581593
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).
Study Overview
Status
Intervention / Treatment
Detailed Description
People with primary immunodeficiency diseases (PID) have a defective immune system and experience recurrent protozoal, bacterial, fungal and viral infections. Antibody deficiencies make up the largest group of PIDs.
The standard care for patients with PID is replacement immunoglobulin (a class of antibodies) solution. Prophylactic treatment with intravenous immunoglobulin (IVIG) solution has been shown to increase the time free from serious infection.
Kedrion IVIG 10% is a new preparation of an immunoglobulin G (IgG) solution. Kedrion IVIG 10% will be given by IV infusion to all study participants. The data collected will help determine whether Kedrion IVIG 10% is suitable for treating PID subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X8
- The Hospital for Sick Children
-
Toronto, Ontario, Canada, M4V1R2
- Gordon Sussman Clinical Research Inc.
-
Toronto, Ontario, Canada, M5G1E2
- Pediatric & Adult Allergy & Clinical Immunology
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Arkansas Children's Hospital
-
-
Florida
-
North Palm Beach, Florida, United States, 33408
- Allergy Associates of the Palm Beaches
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Family Allergy & Asthma Center, PC
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospital and Clinics
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55446
- Midwest Immunology Clinic
-
-
New York
-
Rochester, New York, United States, 14618
- AAIR Research Center
-
-
Ohio
-
Columbus, Ohio, United States, 43235
- Optimed Research, LTD
-
-
Texas
-
Dallas, Texas, United States, 75231
- AARA Research Center
-
Dallas, Texas, United States, 75230
- Dallas Allergy Immunology Research
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University Health Systems
-
-
Washington
-
Spokane, Washington, United States, 99204
- Marycliff Allergy Specialists
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed clinical diagnosis of a Primary Immunodeficiency Disease
- Male or female, ages 2 to 70 years
- Received 300-900 mg/kg of a licensed IVIG therapy at 21 or 28 day intervals for at least 3 months prior to this study
- 2 documented IgG trough levels of ≥ 5 g/L are obtained at two infusion cycles (21 or 28 days) within 12 months (one must be within 6 months) prior to study enrolment
- Non-pregnant females of child-bearing potential who agree to use adequate birth control during the study
- Subject is willing to comply with the protocol
- Authorization to access personal health information.
- Signed the informed consent form and a child assent form, if appropriate.
- If currently participating in a clinical trial with another experimental IVIG may be enrolled if they have received stable IVIG therapy for at least 3 infusion cycles prior to receiving Kedrion IVIG 10% and all inclusion and exclusion criteria are satisfied
- If currently participating in a trial of SCIG can be enrolled if they are switched to IVIG for three infusion cycles (21 or 28 days) prior to enrolment in this study
Exclusion Criteria:
- Has secondary immunodeficiency.
- Newly diagnosed and has not been treated with immunoglobulin or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency.
- Has a history of repeated reactions or hypersensitivity to IVIG or other injectable forms of IgG.
- Has a history of thrombotic events defined by at least 1 event in subject's lifetime.
- Has IgA deficiency and is known to have antibodies to IgA.
- Has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrolment.
- Has significant protein losing enteropathy, nephrotic syndrome or lymphangiectasia.
- Has an acute infection as documented by culture or diagnostic imaging and/or a body temperature exceeding 38.5 °C (101.3 °F) within 7 days prior to screening
- Has a known history or is positive at enrolment for human immunodeficiency virus (HIV) type 1 by NAT, hepatitis B virus (HBsAg and NAT), hepatitis C virus (by NAT), or hepatitis A virus (by NAT).
- Has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study.
- Has an implanted venous access device
- Has profound anemia or persistent severe neutropenia (≤ 1000 neutrophils per mm3)or lymphopenia of less than 500 cells per microliter.
- Has a severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g. atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
- Has a history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to enrolment.
- Has history of epilepsy or multiple episodes of migraine (defined as at least one episode within 6 months of enrolment) not completely controlled by medication.
- Is receiving steroids (oral or parenteral daily dose of ≥ 0.15 mg/kg/day of prednisone or equivalent) OR other immunosuppressive drugs or chemotherapy.
- Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
- Has participated in another clinical study within 3 weeks prior to study enrolment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Kedrion IVIG 10%
Kedrion IVIG 10% treatment.
|
Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.
Time Frame: 13 months
|
The incidence of acute serious bacterial infections, e.g.
bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis, meeting EMA and FDA criteria.
|
13 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Infections Other Than Acute, Serious Bacterial Infections (ASBIs) in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Days Out of Work/School/Daycare Due to Infection in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Days Unable to Perform Normal Daily Activities Due to Infection in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Days on Therapeutic Antibiotics in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Days of Unscheduled Visits to Physicians in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Number of Hospitalizations Due to Infection in ITT Population.
Time Frame: 13 months
|
13 months
|
Days of Hospitalization Due to Infection in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Yearly Hospitalization Rate Due to Infection in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Yearly Hospitalization Duration Due to Infection in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Distribution of All-cause Hospitalizations in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Duration of All-cause Hospitalizations
Time Frame: 13 months
|
13 months
|
Distribution of Fever Episodes in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Duration of Fever Episodes
Time Frame: 13 months
|
13 months
|
IgG Trough Levels at Steady State in the Total ITT Population.
Time Frame: 13 months
|
13 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mirella Calcinai, MD, Kedrion SpA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KB052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Immunodeficiency
-
CSL BehringCompletedPrimary Immunodeficiency (PID)Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
-
CSL LimitedCompleted
-
CSL BehringCompleted
-
Ottawa Hospital Research InstituteOctapharmaUnknownPrimary Immunodeficiency Disease | Secondary ImmunodeficiencyCanada
-
ShireCompleted
-
OctapharmaCompletedPrimary Immunodeficiency (PID)France
-
CHU de ReimsUnknown
-
National Cancer Institute (NCI)RecruitingImmune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune LymphoproliferativeUnited States
-
OctapharmaCompleted
-
Assiut UniversityCompleted
Clinical Trials on Kedrion IVIG 10%
-
Kedrion S.p.A.RecruitingPrimary Immunodeficiency DiseaseItaly, United States, Portugal, Hungary, Russian Federation, Slovakia
-
Kedrion S.p.A.CompletedPrimary Immunodeficiency DiseaseUnited States
-
Sutter HealthCompletedMild Cognitive ImpairmentUnited States
-
Tabriz University of Medical SciencesCompletedRecurrent Implantation FailureIran, Islamic Republic of
-
Vanderbilt University Medical CenterCSL BehringRecruiting
-
Tabriz University of Medical SciencesCompletedRecurrent Pregnancy LossIran, Islamic Republic of
-
Novartis PharmaceuticalsCompleted
-
OctapharmaCompletedAlzheimer's DiseaseUnited States
-
Azidus BrasilSichuan Yuanda Shuyang Pharmaceutical Co., Ltd.Not yet recruitingPrimary Immunodeficiency Disease
-
Biopharma Plasma LLCRecruitingPrimary Immune ThrombocytopeniaUkraine